-
HEROHE Challenge: assessing HER2 status in breast cancer without immunohistochemistry or in situ hybridization
Authors:
Eduardo Conde-Sousa,
João Vale,
Ming Feng,
Kele Xu,
Yin Wang,
Vincenzo Della Mea,
David La Barbera,
Ehsan Montahaei,
Mahdieh Soleymani Baghshah,
Andreas Turzynski,
Jacob Gildenblat,
Eldad Klaiman,
Yiyu Hong,
Guilherme Aresta,
Teresa Araújo,
Paulo Aguiar,
Catarina Eloy,
António Polónia
Abstract:
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly classify breast cancer and define appropriate therapy, which depends on the evaluation of the expression of different biomarkers such as the transmembrane prote…
▽ More
Breast cancer is the most common malignancy in women, being responsible for more than half a million deaths every year. As such, early and accurate diagnosis is of paramount importance. Human expertise is required to diagnose and correctly classify breast cancer and define appropriate therapy, which depends on the evaluation of the expression of different biomarkers such as the transmembrane protein receptor HER2. This evaluation requires several steps, including special techniques such as immunohistochemistry or in situ hybridization to assess HER2 status. With the goal of reducing the number of steps and human bias in diagnosis, the HEROHE Challenge was organized, as a parallel event of the 16th European Congress on Digital Pathology, aiming to automate the assessment of the HER2 status based only on hematoxylin and eosin stained tissue sample of invasive breast cancer. Methods to assess HER2 status were presented by 21 teams worldwide and the results achieved by some of the proposed methods open potential perspectives to advance the state-of-the-art.
△ Less
Submitted 8 November, 2021;
originally announced November 2021.
-
Automated Scoring of Nuclear Pleomorphism Spectrum with Pathologist-level Performance in Breast Cancer
Authors:
Caner Mercan,
Maschenka Balkenhol,
Roberto Salgado,
Mark Sherman,
Philippe Vielh,
Willem Vreuls,
Antonio Polonia,
Hugo M. Horlings,
Wilko Weichert,
Jodi M. Carter,
Peter Bult,
Matthias Christgen,
Carsten Denkert,
Koen van de Vijver,
Jeroen van der Laak,
Francesco Ciompi
Abstract:
Nuclear pleomorphism, defined herein as the extent of abnormalities in the overall appearance of tumor nuclei, is one of the components of the three-tiered breast cancer grading. Given that nuclear pleomorphism reflects a continuous spectrum of variation, we trained a deep neural network on a large variety of tumor regions from the collective knowledge of several pathologists, without constraining…
▽ More
Nuclear pleomorphism, defined herein as the extent of abnormalities in the overall appearance of tumor nuclei, is one of the components of the three-tiered breast cancer grading. Given that nuclear pleomorphism reflects a continuous spectrum of variation, we trained a deep neural network on a large variety of tumor regions from the collective knowledge of several pathologists, without constraining the network to the traditional three-category classification. We also motivate an additional approach in which we discuss the additional benefit of normal epithelium as baseline, following the routine clinical practice where pathologists are trained to score nuclear pleomorphism in tumor, having the normal breast epithelium for comparison. In multiple experiments, our fully-automated approach could achieve top pathologist-level performance in select regions of interest as well as at whole slide images, compared to ten and four pathologists, respectively.
△ Less
Submitted 24 December, 2020; v1 submitted 9 December, 2020;
originally announced December 2020.
-
BACH: Grand Challenge on Breast Cancer Histology Images
Authors:
Guilherme Aresta,
Teresa Araújo,
Scotty Kwok,
Sai Saketh Chennamsetty,
Mohammed Safwan,
Varghese Alex,
Bahram Marami,
Marcel Prastawa,
Monica Chan,
Michael Donovan,
Gerardo Fernandez,
Jack Zeineh,
Matthias Kohl,
Christoph Walz,
Florian Ludwig,
Stefan Braunewell,
Maximilian Baust,
Quoc Dang Vu,
Minh Nguyen Nhat To,
Eal Kim,
** Tae Kwak,
Sameh Galal,
Veronica Sanchez-Freire,
Nadia Brancati,
Maria Frucci
, et al. (11 additional authors not shown)
Abstract:
Breast cancer is the most common invasive cancer in women, affecting more than 10% of women worldwide. Microscopic analysis of a biopsy remains one of the most important methods to diagnose the type of breast cancer. This requires specialized analysis by pathologists, in a task that i) is highly time- and cost-consuming and ii) often leads to nonconsensual results. The relevance and potential of a…
▽ More
Breast cancer is the most common invasive cancer in women, affecting more than 10% of women worldwide. Microscopic analysis of a biopsy remains one of the most important methods to diagnose the type of breast cancer. This requires specialized analysis by pathologists, in a task that i) is highly time- and cost-consuming and ii) often leads to nonconsensual results. The relevance and potential of automatic classification algorithms using hematoxylin-eosin stained histopathological images has already been demonstrated, but the reported results are still sub-optimal for clinical use. With the goal of advancing the state-of-the-art in automatic classification, the Grand Challenge on BreAst Cancer Histology images (BACH) was organized in conjunction with the 15th International Conference on Image Analysis and Recognition (ICIAR 2018). A large annotated dataset, composed of both microscopy and whole-slide images, was specifically compiled and made publicly available for the BACH challenge. Following a positive response from the scientific community, a total of 64 submissions, out of 677 registrations, effectively entered the competition. From the submitted algorithms it was possible to push forward the state-of-the-art in terms of accuracy (87%) in automatic classification of breast cancer with histopathological images. Convolutional neuronal networks were the most successful methodology in the BACH challenge. Detailed analysis of the collective results allowed the identification of remaining challenges in the field and recommendations for future developments. The BACH dataset remains publically available as to promote further improvements to the field of automatic classification in digital pathology.
△ Less
Submitted 17 June, 2019; v1 submitted 13 August, 2018;
originally announced August 2018.
